25th EURADOS Webinar: Release of the nuclear medicine patient in Europe скачать в хорошем качестве

25th EURADOS Webinar: Release of the nuclear medicine patient in Europe

25th EURADOS Webinar: Release of the nuclear medicine patient in Europe: from basics to a computational approach - A Joint EURADOS-EANM initiative Overview The increasing number of nuclear medicine procedures, along with the development of new radiopharmaceuticals, has raised concerns about radiation risks and the radiological protection of not only patients but also medical staff, caregivers, and the general public who come into contact with patients after diagnostic or therapeutic procedures. To ensure adequate radiological protection for these groups, it is essential to consider the radiation emitted by patients during their hospital stay and after release. While radiation exposure for medical staff is well documented due to routine individual monitoring programs and numerous optimization studies, the potential exposure of caregivers and the public after release of the patients from the hospital is less thoroughly studied. Moreover, recommendations for releasing nuclear medicine patients following both therapeutic and diagnostic procedures vary widely across the world. For example, in Europe, the discharge criteria for patients treated with iodine-131 differ between countries. In Germany, patients are required to remain in the hospital for 48 hours after treatment or diagnosis before whole-body activity is measured to determine if release is safe. In contrast, in some other European countries, patients can be released after treatment, moreover, the limits of external dose rates for release of patients after I-131 treatment vary across European countries. To provide scientific information of this variability, in 2017, the European Radiation Dosimetry Group (EURADOS) and the Radiation Protection Committee of the European Association of Nuclear Medicine (EANM) launched a joint project to assess the external dose rates of nuclear medicine patients utilizing biokinetic models, Monte Carlo simulations, and direct measurements to provide scientific data that may guide recommendations on patient release. In this webinar, experts from EURADOS and EANM will present the project's progress, focusing on three radiopharmaceuticals, [99mTc]Tc-HDP/MDP, [18F]F-FDG and Na[131I]I. The webinar will also introduce future plans for radiopharmaceutical therapies, such as [177Lu]Lu-PSMA and [177Lu]Lu-DOTATATE, and discuss efforts for how to harmonize the release criteria for patients after diagnostic and treatment procedures across Europe. Agenda Introduction (Weibo Li) Introduction of EANM RP Committee (Jens Kurth) Legislative aspects of patient discharge in Europe, results from SimpleRad project (Peter Covens) Clinical experience and needs in the radiopharmaceutical therapy (Kristoff Muylle) Computational approach to assess external dose rates from NM patients (Lara Struelens) Q&A and Discussion for future